Rick Doblin founded the Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986, as a “non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.”*.
As a non-profit, MAPS is an unlikely player in a drug-development field dominated by big pharma and its deep pockets. But Doblin’s vision, and the righteousness of MAPS’ cause, has persuaded donors from across the aisles to fund the organization’s research efforts. Now, after decades of focused, strategic effort, MAPS has achieved what could only seem a fantasy at the time of its founding – securing FDA approval to conduct a Phase III study of a psychedelic drug – in this case MDMA – for treatment-resistant PTSD. (Read more on Forbes.com)
